Synthesis and Spectroscopic Characterization of a Dawson Trivanadium-Substituted Polyoxotungstate-Supported {(Cp*Rh)₂}⁴⁺ Complex; (Buⁿ₄N)₅[(Cp*Rh)₂P₂W₁₅V₃O₆₂]

Kenji Nomiya* and Takeshi Hasegawa

Department of Materials Science, Faculty of Science, Kanagawa University, Tsuchiya, Hiratsuka, Kanagawa 259-1293

(Received February 1, 2000; CL-000109)

A novel polyoxotungstate-based 2 : 1-type Cp^*Rh^{2+} complex, $(Bu_4^nN)_5[(Cp^*Rh)_2P_2W_{15}V_3O_{62}]$ ($Cp^* = C_5Me_5$), was synthesized by a direct reaction of the Dawson trivanadium-substituted polyoxotungstate $(Bu_4^nN)_9[\alpha-1,2,3-P_2W_{15}V_3O_{62}]$ with an equimolar amount of $[Cp^*RhCl_2]_2$ in ice-cooled CH_2Cl_2 , without use of silver(I) salts to remove the chloride ions of the precursor.

Numerous examples of Dawson polyoxoanion-supported organometallics have been so far described.¹ Recently, the Dawson triniobium-substituted polyoxotungstate-supported transition metal complexes, $[(CH_3CN)_xM]^{n+}$ (M = Mn^{II}, Fe^{II}, Co^{II} , Ni^{II}, Cu^I, Cu^{II}, Zn^{II}) plus [α -1,2,3-P₂W₁₅Nb₃O₆₂]⁹⁻, and oxygenation catalysis by their all-inorganic, oxidation-resistant precatalysts have been reported.² In particular, as a model of catechol dioxygenase, oxygenation of 3,5-di-tert-butylcatechol by the trivanadium-substituted polyoxotungstate-supported iron(II) complex, $(Bu_4^nN)_7[{(CH_3CN)_xFe^{II}}P_2W_{15}V_3O_{62}]$, is noteworthy.2c Examples of vanadium-substituted polyoxoanion-supported organometallics are $[(CpTi)SiW_9V_3O_{40}]^{4-,3}$ $[(Cp^*Rh)_4V_6O_{19}]^{4a} [\{(cod)Ir\}V_4O_{12}]^{3-} (cod = 1,5-cyclooctadiene)^{4b} and [\{(cod)Ir\}_2V_4O_{12}]^{2-4b} The only one example of the$ Dawson trivanadium-substituted polyoxotungstate-based organometallics is an unusual site-bonding 1 : 1-type compound $(Bu_4^nN)_6[(CpTi) P_2W_{15}V_3O_{62}]$ with C_s symmetry,⁵ and not the initially anticipated C_{3v} symmetry.

In this work, we were successful in isolating a novel polyoxoanion-supported 2 : 1-type Cp^*Rh^{2+} complex, i.e., $(Bu^n_4N)_5[(Cp^*Rh)_2P_2W_{15}V_3O_{62}]$ 1 with C_s symmetry. Herein, we report the synthesis and spectroscopic characterization of 1.

The complex **1** without solvated molecules was prepared by a direct reaction of $(Bu^n_4N)_9[\alpha-1,2,3-P_2W_{15}V_3O_{62}]^3$ with an equimolar amount of $[Cp^*RhCl_2]_2^6$ in ice-cooled CH_2Cl_2 , and was purified by repeated reprecipitation with ice-cooled EtOAc.⁷ The molecular formula of **1** obtained in 59% (0.27 g scale) yield was consistent with all data of complete elemental analysis, TG/DTA, FT-IR, and solution (¹⁸³W, ⁵¹V, ³¹P, ¹H and ¹³C) NMR spectroscopies.⁸ The formation of **1** is shown in Eq 1.

$$(\operatorname{Bu}^{n}_{4}\operatorname{N})_{9}[\operatorname{P}_{2}\operatorname{W}_{15}\operatorname{V}_{3}\operatorname{O}_{62}] + [\operatorname{Cp}^{2}\operatorname{Rh}\operatorname{Cl}_{2}]_{2} \rightarrow (\operatorname{Bu}^{n}_{4}\operatorname{N})_{5}[(\operatorname{Cp}^{2}\operatorname{Rh})_{2}\operatorname{P}_{2}\operatorname{W}_{15}\operatorname{V}_{3}\operatorname{O}_{62}] + 4\operatorname{Bu}^{n}_{4}\operatorname{NCl} \quad (1)$$

The reaction of the B-type deprotonated polyoxotungstate $(Bu_4^nN)_9[P_2W_{15}V_3O_{62}]$ with $[Cp^*RhCl_2]_2$ proceeds in CH_2Cl_2 solvent. In the present synthesis, compared with those of other polyoxoanion-based organometallics,^{1,3,5} there are several note-worthy points. (i) The work-ups of reaction and isolation require the ice-cooled temperature condition. (ii) The reaction proceeds without use of silver(I) salts such as $AgBF_4$ and $AgNO_3$, which have been usually used to remove the chloride ions from the precursors such as $CpTiCl_3$ and $[Cp^*RhCl_2]_2$. (iii) The appropriate solvent is CH_2Cl_2 . Since the reaction does not

take place in a coordinating solvent such as CH₃CN, the reaction does not proceed via [Cp*Rh(CH₃CN)₃]²⁺ which has been in situ used for preparation of the traditional polyoxoanion-supported Cp*Rh²⁺ complex.^{1a,b} (iv) The synthetic stoichiometry to obtain 1 in good yield is 1 : 1 ratio of $(Bu_4^nN)_9[P_2W_{15}V_3O_{62}]$: [Cp*RhCl₂]₂. Other starting ratios, e.g., the 1 : 0.5 ratio in CH₂Cl₂ gave a mixture of several species, including 1 : 1- and 2 : 1-type products, but not a single species. (v) The free by-product Bun₄NCl was completely removed by the repeated reprecipitation with EtOAc, and 1 was isolated as an adduct with 0.2 $Bu_{4}^{n}NCl.$ (vi) The stability of **1** in a coordinating solvent, e.g., CH₃CN, is very low; the supported Cp^{*}Rh²⁺ group is removed from the polyoxoanion surface to produce [Cp*Rh(CH₃CN)₃]²⁺ which is present as the countercation of the $[P_2W_{15}V_3O_{62}]^9$. (vii) The UV-vis absorption titration experiments^{2a} at 320 nm showed a formation of the 2 : 1-composition in CH₂Cl₂, because a break point of absorbance was found at the 2 : 1 ratio of $[Cp^*Rh]^{2+}\!/[P_2W_{15}V_3\,O_{62}]^{9\text{-}}$ (Figure 1). Thus, the composition of **1** is kept in \tilde{CH}_2Cl_2 solution.



Figure 1. Plots of absorbance vs Cp^{*}Rh²⁺/polyoxometalate (POM) molar ratio as UV-vis absorption titration curves at 320 nm in CH_2Cl_2 .

The purity and molecular composition of **1** were established by complete elemental analysis (all elements, and adding up to 99.09%). No solvation was also confirmed by TG/DTA measurements. In the FT-IR spectrum of **1**, the major change relative to $(Bu^n_4N)_9[P_2W_{15}V_3O_{62}]$ was seen in the polyoxometalate region; the 936 and 776 cm⁻¹ bands, respectively assignable to M-O_{terminal} and edge-sharing M-O-M oxygens,⁹ changed to explicit split bands at (957, 941) and (816, 778) cm⁻¹, respectively, and the 877 cm⁻¹ band assignable to corner-sharing M-O-M oxygens⁹ remarkably shifted to lower energy band at 912 cm⁻¹.

The ¹⁸³W NMR in CD_2Cl_2 (Figure 2) confirmed the C_s



symmetry by exhibiting an eight-line spectrum with relative intensities of 2:1:2:2:2:2:2:2 at -60.7, -93.3, -108.4, -128.3, -159.8, -173.7, -180.8 and -186.7 ppm, respectively. The line at -186.7 ppm was considerably broadened. The ⁵¹V NMR in CD₂Cl₂ showed a clean, two-line spectrum of resonances at -524.9 and -550.3 ppm with 2 : 1 intensity ratio (Figure 3), suggesting that the Cp^*Rh^{2+} groups were attached to the $[P_2W_{15}V_3O_{62}]^{9-}$ polyoxotungstate in a way that yielded an overall C_s symmetry complex. The ³¹P NMR spectrum in CD₂Cl₂ showed a simple two-line spectrum with resonances at -8.96 and -13.66 ppm (Figure 4), substantially different from the -6.74 and -14.48 ppm resonances of $(Bu_4^nN)_9[P_2W_{15}V_3O_{62}]$. The ³¹P NMR spectrum confirms the homogeneity of 1 and, thus, the support-site regiospecificity in 1. Further justification for the single product nature of the Cp*Rh²⁺ complex comes from the single Cp^{*} resonance in CD₂Cl₂ seen in the ¹H NMR at 2.12 ppm (C_5Me_5), and ¹³C NMR at 9.4 (C_5Me_5) and 95.1 ppm (C_5 Me₅), respectively.

In summary, the formation of the 2 : 1-type Cp^*Rh^{2+} complex 1 is a rare example, and 1 is the second example which follows the trivanadium-substituted Dawson polyoxotungstate-based 1 : 1-type $CpTi^{3+}$ complex $(Bu^n_4N)_6[(CpTi)P_2W_{15}V_3O_{62}]^{.5}$

This work was supported by a Grant-in-Aid for Scientific Research (C) No. 10640552 from the Ministry of Education, Science, Sports and Culture, Japan.

References and Notes

1

a) M. Pohl, Y. Lin, T. J. R. Weakley, K. Nomiya, M. Kaneko,
H. Weiner, and R. G. Finke, *Inorg. Chem.*, 34, 767 (1995).
b) K. Nomiya, C. Nozaki, M. Kaneko, R. G. Finke, and M. Pohl, *J. Organomet. Chem.*, 505, 23 (1995).
c) M. Pohl, D. K. Lyon, N. Mizuno, K. Nomiya, and R. G. Finke, *Inorg. Chem.*, 34, 1413

(1995). d) K. Nomiya, M. Pohl, N. Mizuno, D. K. Lyon, and R. G. Finke, *Inorg. Synth.*, **31**, 186 (1997). e) T. Nagata, M. Pohl, H. Weiner, and R. G. Finke, *Inorg. Chem.*, **36**, 1366 (1997). f) H. Weiner, J. D. Aiken, III, and R. G. Finke, *Inorg. Chem.*, **35**, 7905 (1996).

- 2 a) H. Weiner, Y. Hayashi, and R. G. Finke, *Inorg. Chem.*, 38, 2579 (1999).
 b) H. Weiner, Y. Hayashi, and R. G. Finke, *Inorg. Chim. Acta*, 291, 426 (1999).
 c) H. Weiner and R. G. Finke, *J. Am. Chem. Soc.*, 121, 9831 (1999).
- 3 a) R. G. Finke, B. Rapko, R. J. Saxton, and P. J. Domaille, J. Am. Chem. Soc., 107, 2947 (1986). b) R. G. Finke, B. Rapko, and P. J. Domaille, Organometallics, 5, 175 (1986). c) R. G. Finke, C. A. Green, and B. Rapko, Inorg. Synth., 27, 128 (1990).
- 4 a) H. K. Chae, W. G. Klemperer, and V. W. Day, *Inorg. Chem.*,
 28, 1423 (1989). b) V. W. Day, W. G. Klemperer, and A. Yagasaki, *Chem. Lett.*, 1990, 1267.
- 5 B. M. Rapko, M. Pohl, and R. G. Finke, *Inorg. Chem.*, **33**, 3625 (1994).
- a) J. W. Kang, K. Moseley, and P. M. Maitlis, J. Am. Chem. Soc., 91, 5970 (1969). b) C. White, A. Yates, and P. M. Maitlis, Inorg. Synth., 29, 228 (1992).
- Synthesis of 1: One precursor $(Bu_{14}^{n}N)_{9}[P_{2}W_{15}V_{3}O_{62}]$ was isolat-7 ed via syntheses of $Na_{12}[P_2W_{15}O_{56}] \cdot 18H_2O$, $K_8H[P_2W_{15}V_3O_{62}]$, $Wa isolate of Wa_{12}[P_2W_{15}O_{56}] \cdot 18H_2O$, $K_8H[P_2W_{15}V_3O_{62}]$. 9H₂O and $(Bu^n_4N)_5H_4[P_2W_{15}V_3O_{62}]$, and a deprotonation of the $(Bu^n_4N)_5H_4$ salt with Bu^n_4NOH ,^{3a} and identified with elemental analysis, FT-IR, ³¹P and ⁵¹V NMR. The other precursor [Cp*RhCl₂], was prepared according to literature methods,⁶ and identified with elemental analysis, ¹H and ¹³C NMR. To an orange solution of 0.50 g (0.081 mmol) of $(Bu_4^nN)_9[P_2W_{15}V_3O_{62}]$ dissolved in 10 cm³ ice-cooled CH₂Cl₂, 0.050 g (0.081 mmol) of solid [Cp*RhCl₂]₂ was added. After 3 h-stirring the resulting dark-red solution in ice-cooled bath, it was added dropwise to 500 cm3 of ice-cooled EtOAc. A brown powder formed. After further 30 min-stirring the suspension, the brown precipitate was collected on a membrane filter (JG $0.2\ \mu\text{m}).$ At this stage yield was $0.35\ \text{g}.$ This powder was redissolved in ca. 2 cm³ of ice-cooled CH₂Cl₂. The dark-red solution was added dropwise to 500 cm³ of ice-cooled EtOAc. After 30 min-stirring, the brown precipitate was collected on a membrane filter (JG 0.2 µm), thoroughly dried by suction, and then dried in vacuo. The brown powder obtained in 59% (0.27 g) yield was soluble in CH₂Cl₂, but insoluble in EtOAc.
- 1: Anal. Found (repeat trials for CHN analysis): C, 21.92 8 (21.69); H, 3.96 (3.86); N, 1.38 (1.22); Cl, 0.25; O, 16.4; P, 1.07; V, 2.61; Rh, 3.20; W, 48.3; total 99.09% (from Mikroanalytisches Labor Pascher, Germany). Calcd for $C_{103,2}H_{217,2}N_{5,2}Cl_{0,2}O_{62}P_2V_3Rh_2W_{15}$ (($Bu_4^nN)_5[(Cp^*Rh)_2$) P₂W₁₅V₃O₆₂]·0.2Buⁿ₄NCl): C, 21.71; H, 3.84; N, 1.28; Cl, 0.12; O, 17.38; P, 1.09; V, 2.68; Rh, 3.61; W, 48.31%. TG/DTA data: no weight loss was observed below 150 °C, suggesting no solvation; decomposition began around 192 °C with an exothermic peak at 260 °C. IR bands in 1700 - 400 cm⁻¹ region (KBr disk): 1636m, 1483m, 1378m, 1153w, 1084s, 1053m, 1026w, 957s, 941s, 912s, 816s, 778s, 670w, 661w, 599w, 565w, 528w, 474w cm⁻¹. ¹H NMR (399.65 MHz, CD₂Cl₂, 25 °C): 2.12 ppm. ¹³C NMR (100.40 MHz, CD₂Cl₂, 25 °C): 9.4 (C₅Me₅), 95.1 (C₅Me₅) ppm. ³¹P NMR (161.70 MHz, CD₂Cl₂, 25 °C): -8.96, -13.66 ppm. ⁵¹V NMR (104.95 MHz, CD₂Cl₂, 25 °C): -524.9, -550.3 ppm. ¹⁸³W NMR (16.59 MHz, CD₂Cl₂, 25 °C): -60.7, -93.3, -108.4, -128.3, -159.8, -173.7, -180.8, -186.7 ppm.
- C. Rocchiccioli-Deltcheff and R. Thouvenot, *Spectroscop. Lett.*, 12, 127 (1979).